We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Reflux Surgery May Not End Need for Medication

By HospiMedica staff writers
Posted on 29 May 2001
A 10-year follow-up study on 239 patients with complicated gastroesophageal reflux disease (GERD) who had participated in an earlier trial of medical versus surgical antireflux treatments has found that more than half of the surgery patients used antireflux medications regularly. More...
The follow-up study, conducted by researchers at various U.S. Department of Veterans Affairs Medical Centers, was published in The Journal of the American Medical Association (JAMA, 2001;285:2331-2338).

The initial study suggested that surgery was the best treatment for GERD. The advantages of surgery were assumed to be permanent relief, elimination of the need for antireflux mediations, and prevention of cancer. The follow-up study found none of these benefits. Specifically, 92% of the medical patients and 62% of the surgical patients reported regular use of antireflux medications. No statistical difference between medical and surgery patients was found in the occurrence of esophageal cancer. Also, a number of patients in both groups had one or more antireflux operations (10% of medical patients and 16% of surgical patients.)

As a result, the researchers suggest that doctors should advise patients with GERD that surgery may not eliminate the need for medication and that the procedure will not prevent cancer of the esophagus or the need for another operation. One finding that the researchers could not explain was that about 40% of the surgery group but only 28% of the medical group died. Nearly half of the surgery patient deaths were from heart attacks. The researchers suggest that doctors tell GERD patients who have surgery to make an extra effort to control their risk factors for heart disease.


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.